This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Top FDA Drug Approval Pickers

BOSTON ( TheStreet) -- Congratulations to the three winners of TheStreet's FDA Drug Approval Contest. Each compiled impressive 10-1 records correctly predicting FDA drug approvals and rejections during the busy month of October.

The winners:

BioTrekker: A professional healthcare investor (yes, he works at a hedge fund!) whose only miscue was incorrectly predicting an FDA delay for Avanir Pharmaceuticals' (AVNR) Nuedexta. For compliance reasons, BioTrekker asked not to be identified by his real name.

Superrfly: Also known as Matthew Wenzlick, a 21-year-old college student majoring in finance. Wenzlick has been trading stocks since January 2009 and has gradually shifted his focus towards the biotech sector. "Superrfly" didn't start off the contest so super, he got the Hospira (HSP - Get Report) decision wrong at the top of October, but he was perfect after that.

Our third winner, Joe, remains behind a curtain. Joe didn't respond to my email informing him of his good fortune, so perhaps he's just shy. Joe may not want to be identified but I can still congratulate him for an almost-perfect drug approval prediction record. His only blemish was incorrectly predicting the rejection of Forest Labs' (FRX) antibiotic.

To quickly recap the contest, these three winners beat out 91 other contestants in correctly guessing the outcome of 11 FDA drug approval decisions in October. What's most impressive about BioTrekker, Superrfly and Joe is that they were among only a handful of contestants who correctly predicted the FDA's rejection of Amylin Pharmaceuticals' (AMLN) diabetes drug Bydureon. To me, that decision was the biggest surprise of the month and it was the turning point for the contest.

Guessing right on the Alkermes (ALKS - Get Report) approval or the rejections handed to Vivus (VVUS - Get Report) and Arena Pharmaceuticals (ARNA - Get Report) was fairly easy, but nailing the tough-to-call outcomes like Avanir and Alexza Pharmaceuticals (ALXA - Get Report) showed true skill.

BioTrekker came oh-so close to running the table and being the sole contest winner because he tells me he was leaning positive on Avanir.

How did our winners manage to go 10-1?

"You have to do research independent of the companies and sell-side analysts," says BioTrekker. "Reading press releases is not due diligence. There is a lot of information to be found on the Internet. Use Google, but go beyond the first page of search results.

"Run down obscure things. A lot of drugs are old and repurposed. Management teams and companies often have histories they don't necessarily want you to know about. Be a skeptic," he adds.

Superrfly i.e. Wenzlick says he pays attention to whether a drug is unique and targets a large market. "While harder to obtain approval, the unique drugs seem to be the biggest moneymakers for investors."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ALXA $1.92 -1.03%
ALKS $58.15 -6.60%
AVNR $16.96 0.00%
ARNA $4.22 -6.01%
BIOD $1.17 2.63%

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs